---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024920"
form_type: "8-K"
ticker: null
cik: "0001827506"
company_name: "Tourmaline Bio, Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:53:37.688315+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Talaris CEO departs; CFO Fenton takes interim CEO role; strategic review underway

## Summary
- Scott Requadt left as CEO and President effective May 26, 2023; no disagreement cited.
- CFO Mary Kay Fenton appointed interim CEO and President, remaining CFO.
- Requadt to receive $50,000/month as strategic advisor through August 26, 2023.
- Company conducting strategic review including possible business combination or divestiture.
- Workforce reduction previously announced; no timetable set for review.

## SEC filing metadata
- accession: 0000950170-23-024920
- form_type: 8-K
- cik: 0001827506
- company_name: Tourmaline Bio, Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/tals-20230526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024920
- JSON: https://secwatch.observer/filing/0000950170-23-024920.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024920.txt

## Key facts
- Executive change
  Mary Kay Fenton was appointed as Interim Chief Executive Officer and President at Tourmaline Bio, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer and President
  source text: Effective May 26, 2023, the Board of Directors of the Company (the “ Board ”) appointed Mary Kay Fenton, the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President, until a successor is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm
- Executive change
  Scott Requadt departed as Chief Executive Officer and President at Tourmaline Bio, Inc..
  - Action: left
  - Role: Chief Executive Officer and President
  source text: As previously announced, effective May 26, 2023, Scott Requadt left his role as Chief Executive Officer and President of Talaris Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm
- Executive change
  Scott Requadt resigned as Director at Tourmaline Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: Mr. Requadt notified the Company of his intent to resign from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023024920/0000950170-23-024920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.